Clinical Cancer Research · 2008 · 68 citations · 30 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyTargeted Cancer TherapyTargeted TherapyGemcitabine-based TherapyLuciferase ReportersPdgfr InhibitorsPlatelet-derived Growth Factor InhibitionPlatelet-derived Growth Factor Receptor SignalingPlatelet-derived Growth Factor ReceptorsTumor Uptake KineticsTumor Uptake Mechanisms
PURPOSE: Platelet-derived growth factor receptor beta (PDGFRbeta), frequently activated in malignant mesothelioma, is a promising cancer therapeutic target. Imatinib mesylate (STI571; Glivec) is a selective inhibitor of tyrosine kinases as bcr-abl, c-kit, c-fms, and PDGFRbeta and enhances tumor drug uptake by reducing the interstitial fluid pressure. We previously showed that imatinib mesylate synergizes with gemcitabine and pemetrexed in PDGFRbeta-positive mesothelioma cells. Here, we aimed at investigating these combined treatments in a novel mesothelioma model. EXPERIMENTAL DESIGN: REN mesothelioma cells, infected with a lentiviral vector carrying the luciferase gene, were injected in the peritoneum of severe combined immunodeficient mice. This model allowed imaging of live animals treated with pemetrexed or gemcitabine chemotherapeutics, or with imatinib mesylate alone, as well as with a combination of gemcitabine and imatinib mesylate. RESULTS: We show here that, consistent with our previous in vitro studies, gemcitabine inhibited tumor growth, whereas pemetrexed was ineffective, even at the highest dosage tested. Compared with monotreatment, the combination of gemcitabine with imatinib mesylate led to a further tumor growth inhibition and improved mice survival, by a decrease rate of tumor cell proliferation and an increase in number of apoptotic tumor cells. CONCLUSIONS: Imatinib mesylate enhances the therapeutic response to gemcitabine, in accordance with our previous in vitro data. These in vivo results validate imatinib mesylate and gemcitabine as a combination treatment of malignant mesothelioma, also in view of its known positive effects on tumor drug uptake. These evidences provide the rationale for the currently ongoing clinical trials.
30
Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text
Medicine, Hematology, Oncology +17
The European mesothelioma epidemic
Julian Peto, Adriano Decarli, Carlo La Vecchia et al. · British Journal of Cancer · 1999 · 900 citations · Full text
Medicine, Demography, Oncology +17
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Kristian Pietras, Kristofer Rubin, Tobias Sjöblom et al. · PubMed · 2002 · 435 citations
Medicine, Oncology, Pharmacology +16
Asbestos Exposure, Pleural Mesothelioma, and Serum Osteopontin Levels
Harvey I. Pass, Dan Lott, Fulvio Lonardo et al. · New England Journal of Medicine · 2005 · 358 citations · Full text